Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Halozyme Appoints SVP, COO | Contract Pharma
Promotions & Moves

Halozyme Appoints SVP, COO

Gergen responsible for corporate development of ENHANZE platform

Mark J. Gergen has been appointed senior vice president and chief operating officer at Halozyme Therapeutics, Inc. He reports to Dr. Helen Torley, president and chief executive officer.

Mr. Gergen will be responsible for corporate development, including the management of Halozyme’s ENHANZE platform collaborations and overseeing the global product teams responsible for planning development and commercialization of its oncology pipeline, including clinical operations and clinical collaborations.

“Mark brings a wealth of business development and operational experience that will be essential as we execute our plan to accelerate growth of the ENHANZE platform and develop and commercialize multiple oncology drugs,” said Dr. Torley. “With more than 20 years of healthcare and biotech experience, he will be a strong addition to our management team as we execute our growth strategy.”
Mr. Gergen joins the company from Mirati Therapeutics, an oncology biotech, where he was executive vice president and chief operating officer responsible for the strategy, corporate development, finance, investor relations, human resources, information technology and legal functions. He executed multiple successful partnerships, collaborations and licensing agreements.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters